3-benzofuran-5-yl-1-(2,6-dihydroxy-4-methyl-phenyl)-propan-1-one | 701936-17-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: 3-benzofuran-5-yl-1-(2,6-dihydroxy-4-methyl-phenyl)-propan-1-one
• 英文别名: 3-(1-Benzofuran-5-yl)-1-(2,6-dihydroxy-4-methylphenyl)propan-1-one
• CAS: 701936-17-6
• 化学式: C₁₈H₁₆O₄
• 分子量: 296.323
• InChiKey: JUMBPJHNJKFJSP-UHFFFAOYSA-N

物化性质

• 沸点：
  487.8±45.0 °C(Predicted)
• 密度：
  1.298±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  70.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-benzofuran-5-yl-1-(2,6-dihydroxy-4-methyl-phenyl)-propan-1-one 在 甲醇 、 potassium carbonate 、 肼 作用下， 以 乙二醇 、 丙酮 为溶剂， 反应 24.0h， 生成 2-[3-(2-benzofuran-5-yl-ethyl)-6-methyl-1H-indazol-4-yloxy]-β-D-glucopyranoside
  参考文献：
  名称：

  Heteroaryl-O-glucosides as novel sodium glucose co-transporter 2 inhibitors. Part 1

  摘要：

  A series of benzo-fused heteroaryl-O-glucosides was synthesized and evaluated in SGLT1 and 2 cell-based functional assays. Indole-O-glucoside 10a and benzimidazole-O-glucoside 18 exhibited potent in vitro SGLT2 inhibitory activity. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.08.067
• 作为产物：
  描述：

  1-苯并呋喃-5-甲醛 在 palladium on activated charcoal 盐酸 、 氢氧化钾 、 氢气 作用下， 以 1,4-二氧六环 、 乙醇 、 乙酸乙酯 、 异丙醇 为溶剂， 生成 3-benzofuran-5-yl-1-(2,6-dihydroxy-4-methyl-phenyl)-propan-1-one
  参考文献：
  名称：

  Heteroaryl-O-glucosides as novel sodium glucose co-transporter 2 inhibitors. Part 1

  摘要：

  A series of benzo-fused heteroaryl-O-glucosides was synthesized and evaluated in SGLT1 and 2 cell-based functional assays. Indole-O-glucoside 10a and benzimidazole-O-glucoside 18 exhibited potent in vitro SGLT2 inhibitory activity. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.08.067

文献信息

• Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
  申请人：Frick Wendelin

  公开号：US20050014704A1

  公开（公告）日：2005-01-20

  Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof. The invention relates to substituted aromatic fluoroglycoside derivatives of the formula I in which the radicals have the stated meanings, and their physiologically tolerated salts and process for their preparation. The compounds are suitable for example as antidiabetics.

  新型芳香族氟糖苷衍生物，包含这些化合物的药物，以及它们的用途。该发明涉及公式I的取代芳香族氟糖苷衍生物，其中基团具有所述含义，以及它们的生理耐受盐和制备过程。这些化合物例如适用于抗糖尿病药物。
• N-substituted pyrazole-O-glycoside derivatives and therapeutic agent for diabetes containing the same
  申请人：Ajinomoto Co., Inc.

  公开号：US20040110936A1

  公开（公告）日：2004-06-10

  The present invention relates to pyrazole derivatives represented by the following formulas and analogues thereof, which can be used for a therapeutic agent for diabetes. 1

  本发明涉及以下公式及其类似物所表示的吡唑衍生物，可用作糖尿病治疗药物。1
• Substituted indazole-O-glucosides
  申请人：Patel Mona

  公开号：US20050032711A1

  公开（公告）日：2005-02-10

  Substituted indazole-O-glucosides, compositions containing them, and methods of using them, for example for the treatment of diabetes and Syndrome X are disclosed.

  本发明揭示了替代的吲哚-O-葡萄糖苷，含有它们的组合物以及使用它们的方法，例如用于治疗糖尿病和X综合征。
• NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF
  申请人：FRICK Wendelin

  公开号：US20080108580A1

  公开（公告）日：2008-05-08

  Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof. The invention relates to substituted aromatic fluoroglycoside derivatives of the formula I in which the radicals have the stated meanings, and their physiologically tolerated salts and process for their preparation. The compounds are suitable for example as antidiabetics.

  小说芳香族氟代糖苷衍生物，含有这些化合物的药物，以及它们的使用。本发明涉及式I的取代芳香族氟代糖苷衍生物，其中基团具有所述的含义，以及其生理上耐受的盐和制备过程。这些化合物例如适用于抗糖尿病药物。
• SUBSTITUTED INDAZOLES-O- GLUCOSIDES
  申请人：Patel Mona

  公开号：US20090099104A1

  公开（公告）日：2009-04-16

  Substituted indazole-O-glucosides, compositions containing them, and methods of using them, for example for the treatment of diabetes and Syndrome X are disclosed.

  本发明涉及替代的吲唑-O-葡萄糖苷，包含它们的组合物以及使用它们的方法，例如用于治疗糖尿病和X综合症。